Literature DB >> 11758095

[Interferon alpha-associated agranulocytosis during clozapine treatment. Case report and status of current knowledge].

M Schäfer1, F Schmidt, H Grunze, G Laakmann, K Loeschke.   

Abstract

Little is known about possibilities of chronic hepatitis C treatment with interferon-alpha (IFN-alpha) in psychiatric patients continuously taking antipsychotics. We report on a 28-year-old hepatitis C-positive man with paranoid psychosis. He was successfully treated with clozapine, an atypical antipsychotic drug which is known for the risk of granulocytopenia and agranulocytosis. With doses up to 200 mg/day over 3 years, he showed no remarkable changes in WBC. Because of the chronic hepatitis C with genotype 3a, additional treatment was started with IFN-alpha (s.c., 3 x 6 million IU/week). After 2 months of therapy he developed a severe agranulocytosis. Both clozapine and IFN-alpha were discontinued, and his WBC returned to normal. Results from bone marrow examination were compatible with a toxic reaction possibly caused by either or both medications. We discuss possible problems with IFN-alpha during the treatment of psychiatric patients, interactions with psychiatric medication, and hematotoxic side effects like those from clozapine. We recommend combining IFN-alpha with less "toxic" antipsychotics and weekly checks of WBC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11758095     DOI: 10.1007/s001150170022

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  3 in total

Review 1.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  Hepatitis C treatment of patients with bipolar disorder: a case series.

Authors:  Muhamad Aly Rifai
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

3.  The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice.

Authors:  Meghan May; Megan Beauchemin; Calvin Vary; Deborah Barlow; Karen L Houseknecht
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.